Physician profile
Jacob A Bailey
NPI 1780363275
$2,334.11
in general payments reported to CMS, 2019-2025
26 companies · $779 in 2025
The $779 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $248 · 2024: $1,308 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $437.06 | 2023-2025 | |
| Pfizer INC. | $300.80 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $262.14 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $233.73 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $164.79 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Gilead Sciences, INC. | $128.00 | 2025 | Yeztugo |
| Amgen INC. | $123.27 | 2023-2025 | Evenity, Prolia, Krystexxa |
| Exact Sciences Corporation | $87.79 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $79.88 | 2023-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $77.79 | 2024-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $56.70 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $56.23 | 2023-2024 | |
| Xeris Pharmaceuticals, INC. | $48.45 | 2024 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.89 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $32.97 | 2024 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $28.98 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boston Scientific Corporation | $27.09 | 2025 | Cds - Mct/Cem Monitoring |
| Actelion Pharmaceuticals US, INC. | $21.30 | 2024 | Uptravi, Opsumit |
| Becton, Dickinson and Company | $18.14 | 2024 | Bd Onclarity |
| Sumitomo Pharma America, INC. | $17.93 | 2025 | Myfembree |
| Radius Health, INC. | $17.38 | 2025 | Tymlos |
| Intra-Sana Laboratories | $16.90 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Abbott Laboratories | $15.77 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $15.65 | 2023 | Nexletol |
| Aimmune Therapeutics, INC. | $15.54 | 2024 | |
| Shield Therapeutics INC | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.